XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Summary of Significant Accounting Policies (Details Textual)
6 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Aug. 09, 2017
USD ($)
Cash, Uninsured Amount $ 69,400,000 $ 69,400,000      
Inventory Valuation Reserves, Ending Balance 0 0 $ 0    
Finance Lease, Liability, Total 0 $ 0 0    
Number of Reporting Units   1      
Goodwill, Impairment Loss 0   0    
Revenue from Contract with Customer, Including Assessed Tax   $ 8,208,000 30,000    
Reserves for Sales Returns and Consumer and Trade Promotion Obligations 1,300,000 1,300,000   $ 0  
Contract with Customer, Asset, before Allowance for Credit Loss, Total $ 0 0 0    
Advertising Expense   13,900,000 0    
Dilutive Securities, Effect on Basic Earnings Per Share, Total   $ 0 0    
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Customer A [Member]          
Concentration Risk, Percentage   30.20%      
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Customer B [Member]          
Concentration Risk, Percentage   19.60%      
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Customer C [Member]          
Concentration Risk, Percentage   12.30%      
Grant [Member]          
Revenue from Contract with Customer, Including Assessed Tax   $ 0 30,430    
VAZALORE [Member]          
Revenue from Contract with Customer, Including Assessed Tax   8,200,000      
VAZALORE 81 mg Dose [Member]          
Revenue from Contract with Customer, Including Assessed Tax   $ 5,600,000      
VAZALORE 81 mg Dose [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]          
Concentration Risk, Percentage   68.00%      
VAZALORE 325 mg Dose [Member]          
Revenue from Contract with Customer, Including Assessed Tax   $ 2,600,000      
VAZALORE 325 mg Dose [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]          
Concentration Risk, Percentage   32.00%      
Term Loan Facility [Member] | Silicon Valley Bank (SVB) [Member]          
Debt Instrument, Face Amount     $ 600,000   $ 7,500,000